Method for producing metabolites from omeprazole using bacterial cytochrome P450, and composition for same
The present invention relates to a novel method for producing metabolites from omeprazole using bacterial cytochrome P450, and a composition therefor, and more specifically, to a composition and a kit for producing a 5′-hydroxyl product from omeprazole, containing bacterial cytochrome P450 BM3 (CYP102A1) or mutants thereof, and to a method for producing the same. The composition, the kit, and the method are capable of economically and highly efficiently mass-producing the 5′-hydroxyl product from the omeprazole, and thus will significantly contribute to development of a novel drug using metabolites from the omeprazole.
1. A mutant of CYP102A1, wherein the mutant of CYP102A1 has mutations R48L, F88V and L189Q based on SEQ ID NO: 16 of the wild-type CYP102A1.
2. A composition for producing a 5′-hydroxyl product from omeprazole, containing a mutant of enzyme CYP102A1, wherein wild-type CYP102A1 comprises the amino acid sequence of SEQ ID NO: 16, and wherein the mutant of CYP102A1 has mutations R48L, F88V and L189Q based on SEQ ID NO: 16.
3. The composition of claim 2 , wherein the omeprazole is a racemate containing S- or R-omeprazole which is an enantiomer, or an enantiomer of the S- and R-omeprazole at a ratio of 50:50.
4. A kit for producing a 5′-hydroxyl product from omeprazole, comprising an NADPH-generating system and a mutant of CYP102A1,
wherein the mutant of CYP102A1 has mutations on the sequence of a wild-type CYP102A1, said wild-type CYP102A1 comprising the amino acid sequence of SEQ ID NO: 16, and wherein the mutations comprise R48L, F88V and L189Q based on SEQ ID NO: 16.
5. The kit of claim 4 , wherein the NADPH-generating system contains glucose 6-phosphate, NADP + and yeast glucose-6-phosphate dehydrogenase.
6. A method for producing a 5′-hydroxyl product from omeprazole, including reacting the omeprazole with a mutant of enzyme CYP102A1,
wherein a wild-type CYP102A1 comprises the amino acid sequence of SEQ ID NO: 16, and wherein the mutant of CYP102A1 has mutations R48L, F88V and L189Q based on SEQ ID NO: 16.
7. The method of claim 6 , further comprising: adding an NADPH-generating system.